Amgen has announced that its head of R&D, Sean Harper, is leaving to pursue opportunities in early-stage biotech. The company said he would be succeeded by David Resse, currently the company’s senior vice president of translational sciences and oncology. The company also announced that Murdo Gordon, currently chief commercial officer at Bristol-Myers Squibb, will take over the role of Amgen’s executive vice president of global commercial operation from Anthony Hooper.